Ruiz-Ortega, M., Rodrigues-Diez, R. R., Lavoz, C. & Rayego-Mateos, S. Special issue “diabetic nephropathy: Diagnosis, prevention and treatment”. J. Clin. Med. 9, 813. https://doi.org/10.3390/jcm9030813 (2020).
Thomas, M. C., Cooper, M. E. & Zimmet, P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat. Rev. Nephrol. 12, 73–81. https://doi.org/10.1038/nrneph.2015.173 (2016).
Breyer, M. D. & Susztak, K. The next generation of therapeutics for chronic kidney disease. Nat. Rev. Drug Discov. 15, 568–588. https://doi.org/10.1038/nrd.2016.67 (2016).
Fouque, D. et al. Achievement of 2009 and 2017 kidney disease: Improving global outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients. Clin. Kidney J. 11, 710–719. https://doi.org/10.1093/ckj/sfy015 (2018).
Kim, K. S., Park, S. W., Cho, Y. W. & Kim, S. K. Higher prevalence and progression rate of chronic kidney disease in elderly patients with type 2 diabetes mellitus. Diabetes Metab. J. 42, 224–232. https://doi.org/10.4093/dmj.2017.0065 (2018).
WHO. World Health Statistics 2022 Geneva. http://www.who.int/news/item/20-05-2022-world-health-statistics-2022 (World Health Organization, 2022).
Yuan, C. M., Nee, R., Ceckowski, K. A., Knight, K. R. & Abbott, K. C. Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin. Kidney J. 10, 257–262. https://doi.org/10.1093/ckj/sfw112 (2017).
Report UA. End-stage Renal Disease in the United States (2014).
Cheng, H. T., Xu, X., Lim, P. S. & Hung, K. Y. Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015. Diabetes Care 44, 89–97. https://doi.org/10.2337/dc20-1913 (2021).
Bowe, B. et al. Changes in the US burden of chronic kidney disease from 2002 to 2016: An analysis of the global burden of disease study. JAMA Netw. Open 1, e184412. https://doi.org/10.1001/jamanetworkopen.2018.4412 (2018).
Xie, Y. et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 94, 567–581. https://doi.org/10.1016/j.kint.2018.04.011 (2018).
Hill, C. J. et al. Obesity and kidney disease in type 1 and 2 diabetes: An analysis of the National Diabetes Audit. QJM 106, 933–942. https://doi.org/10.1093/qjmed/hct123 (2013).
Todd, J. N. et al. Genetic evidence for a causal role of obesity in diabetic kidney disease. Diabetes 64, 4238–4246. https://doi.org/10.2337/db15-0254 (2015).
Leehey, D. J. et al. BP and renal outcomes in diabetic kidney disease: The veterans affairs nephropathy in diabetes trial. Clin. J. Am. Soc. Nephrol. 10, 2159–2169. https://doi.org/10.2215/cjn.02850315 (2015).
Giunti, S., Barit, D. & Cooper, M. E. Mechanisms of diabetic nephropathy: Role of hypertension. Hypertension 48, 519–526. https://doi.org/10.1161/01.HYP.0000240331.32352.0c (2006).
Raile, K. et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: Effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 30, 2523–2528. https://doi.org/10.2337/dc07-0282 (2007).
Möllsten, A. et al. Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: A nationwide population-based cohort study. Diabetes 59, 1803–1808. https://doi.org/10.2337/db09-1744 (2010).
Thomas, B. The global burden of diabetic kidney disease: Time trends and gender gaps. Curr. Diab. Rep. 19, 18. https://doi.org/10.1007/s11892-019-1133-6 (2019).
Deng, Y. et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. Front. Endocrinol. 12, 672350. https://doi.org/10.3389/fendo.2021.672350 (2021).
Pan, X. et al. The burden of diabetes-related chronic kidney disease in China from 1990 to 2019. Front. Endocrinol. 13, 892860. https://doi.org/10.3389/fendo.2022.892860 (2022).
Liu, M. et al. Burden of diabetes, hyperglycaemia in China from to 2016: Findings from the 1990 to 2016, global burden of disease study. Diabetes Metab. 45, 286–293. https://doi.org/10.1016/j.diabet.2018.08.008 (2019).
GBD 2019 Diabetes Mortality Collaborators. Diabetes mortality and trends before 25 years of age: An analysis of the Global Burden of Disease Study 2019. Lancet Diabetes Endocrinol. 10, 177. https://doi.org/10.1016/s2213-8587(21)00349-1 (2022).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306. https://doi.org/10.1056/NEJMoa1811744 (2019).
WHO. World Report on Ageing and Health. http://www.who.int/publications/i/item/9789241565042 (2015).
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222. https://doi.org/10.1016/s0140-6736(20)30925-9 (2020).
Murray, C. J. Quantifying the burden of disease: The technical basis for disability-adjusted life years. Bull. World Health Organ. 72, 429–445 (1994).
Xie, J. et al. Global burden of type 2 diabetes in adolescents and young adults, 1990–2019: Systematic analysis of the Global Burden of Disease Study 2019. BMJ. https://doi.org/10.1136/bmj-2022-072385 (2022).
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1–S127. https://doi.org/10.1016/j.kint.2022.06.008 (2022).
GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: A comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1160–1203. https://doi.org/10.1016/s0140-6736(20)30977-6 (2020).
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1223–1249. https://doi.org/10.1016/s0140-6736(20)30752-2 (2020).
Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010 (2020).
Kim, H. J., Fay, M. P., Feuer, E. J. & Midthune, D. N. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19, 335–351. https://doi.org/10.1002/(sici)1097-0258(20000215)19:3%3c335::aid-sim336%3e3.0.co;2-z (2000).
Mason, K. O., Mason, W. M., Winsborough, H. H. & Poole, W. Some methodological issues in cohort analysis of archival data. Am. Sociol. Rev. 38, 242–258 (1973).
Yang, Y., Fu, W. J. & Land, K. C. A Methodological Comparison of Age-Period-Cohort Models: Intrinsic Estimator and Conventional Generalized Linear Models Vol. 34 (Blackwell Publishing, 2004).
GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019. Lancet 396, 1135–1159. https://doi.org/10.1016/s0140-6736(20)31404-5 (2019).
GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1250–1284. https://doi.org/10.1016/s0140-6736(20)30750-9 (2020).
Anderson, S. & Brenner, B. M. The aging kidney: Structure, function, mechanisms, and therapeutic implications. J. Am. Geriatr. Soc. 35, 590–593. https://doi.org/10.1111/j.1532-5415.1987.tb01407.x (1987).
Sobamowo, H. & Prabhakar, S. S. The kidney in aging: Physiological changes and pathological implications. Prog. Mol. Biol. Transl. Sci. 146, 303–340. https://doi.org/10.1016/bs.pmbts.2016.12.018 (2017).
Zhang, Q. L. & Rothenbacher, D. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health 8, 117. https://doi.org/10.1186/1471-2458-8-117 (2008).
Goto, N. A. et al. The association between chronic kidney disease, falls, and fractures: A systematic review and meta-analysis. Osteoporos Int. 31, 13–29. https://doi.org/10.1007/s00198-019-05190-5 (2020).
Tuttle, K. R. et al. Diabetic kidney disease: A report from an ADA Consensus Conference. Am. J. Kidney Dis. 64, 510–533. https://doi.org/10.1053/j.ajkd.2014.08.001 (2014).
Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364, 937–952. https://doi.org/10.1016/s0140-6736(04)17018-9 (2004).
Hope, D. C. D., Tan, T. M. M. & Bloom, S. R. No guts, no loss: Toward the ideal treatment for obesity in the twenty-first century. Front. Endocrinol. 9, 442. https://doi.org/10.3389/fendo.2018.00442 (2018).
Farsang, C. Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial. Adv. Ther. 31, 333–344. https://doi.org/10.1007/s12325-014-0107-y (2014).
Kohan, D. E. & Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 86, 896–904. https://doi.org/10.1038/ki.2014.143 (2014).
Hypertension in Diabetes Study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J. Hypertens. 11, 309–317. https://doi.org/10.1097/00004872-199303000-00012 (1993).
de Boer, I. H. et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305, 2532–2539. https://doi.org/10.1001/jama.2011.861 (2011).
Nichols, G. A., Vupputuri, S. & Lau, H. Medical care costs associated with progression of diabetic nephropathy. Diabetes Care 34, 2374–2378. https://doi.org/10.2337/dc11-0475 (2011).
Maric-Bilkan, C. Obesity and diabetic kidney disease. Med. Clin. N. Am. 97, 59–74. https://doi.org/10.1016/j.mcna.2012.10.010 (2013).
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 98, S1–S115. https://doi.org/10.1016/j.kint.2020.06.019 (2020).
Liew, A. et al. Asian pacific society of nephrology clinical practice guideline on diabetic kidney disease. Nephrology (Carlton) 25(Suppl 2), 12–45. https://doi.org/10.1111/nep.13785 (2020).
Expert Group of Chinese Society of Nephrology. Chinese guidelines for diagnosis and treatment of diabetic kidney disease. Chin. J. Nephrol. 37, 255–304. https://doi.org/10.3760/cma.j.cn441217-20201125-00041 (2021).
Carey, R. M., Muntner, P., Bosworth, H. B. & Whelton, P. K. Prevention and control of hypertension: JACC health promotion series. J. Am. Coll. Cardiol. 72, 1278–1293. https://doi.org/10.1016/j.jacc.2018.07.008 (2018).
Aburto, N. J. et al. Effect of lower sodium intake on health: Systematic review and meta-analyses. BMJ 346, f1326. https://doi.org/10.1136/bmj.f1326 (2013).
Cirillo, M. et al. Sodium intake and kidney function in the general population: An observational, population-based study. Clin. Kidney J. 14, 647–655. https://doi.org/10.1093/ckj/sfaa158 (2021).
GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 393, 1958–1972. https://doi.org/10.1016/s0140-6736(19)30041-8 (2019).
Mills, K. T. et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 315, 2200–2210. https://doi.org/10.1001/jama.2016.4447 (2016).
Krone, O., Kenntner, N., Ebner, N., Szentiks, C. A. & Dänicke, S. Comparing erosion and organ accumulation rates of lead and alternative lead-free ammunition fed to captive domestic ducks. Ambio 48, 1065–1071. https://doi.org/10.1007/s13280-019-01183-0 (2019).
Gillis, B. S., Arbieva, Z. & Gavin, I. M. Analysis of lead toxicity in human cells. BMC Genom. 13, 344. https://doi.org/10.1186/1471-2164-13-344 (2012).
Safar, Z., Labib, M. W. & Gertler, A. W. Development and validation of a lead emission inventory for the Greater Cairo area. J. Adv. Res. 5, 551–562. https://doi.org/10.1016/j.jare.2013.07.003 (2014).
Staessen, J. A. et al. Interpretation of population health metrics: Environmental lead exposure as exemplary case. Hypertension 75, 603–614. https://doi.org/10.1161/hypertensionaha.119.14217 (2020).
Blakely, T. et al. Health, health inequality, and cost impacts of annual increases in tobacco tax: Multistate life table modeling in New Zealand. PLoS Med. 12, e1001856. https://doi.org/10.1371/journal.pmed.1001856 (2015).
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 390, 2627–2642. https://doi.org/10.1016/s0140-6736(17)32129-3 (2017).
Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766–781. https://doi.org/10.1016/s0140-6736(14)60460-8 (2014).
Sakaguchi, Y. et al. Hypomagnesemia in type 2 diabetic nephropathy: A novel predictor of end-stage renal disease. Diabetes Care 35, 1591–1597. https://doi.org/10.2337/dc12-0226 (2012).
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 389, 37–55. https://doi.org/10.1016/s0140-6736(16)31919-5 (2017).
Beard, J. R. et al. The World report on ageing and health: A policy framework for healthy ageing. Lancet 387, 2145–2154. https://doi.org/10.1016/s0140-6736(15)00516-4 (2016).
Pan, A. et al. Changes in red meat consumption and subsequent risk of type 2 diabetes mellitus: Three cohorts of US men and women. JAMA Intern. Med. 173, 1328–1335. https://doi.org/10.1001/jamainternmed.2013.6633 (2013).
Barone Gibbs, B. et al. Sedentary time, physical activity, and adiposity: Cross-sectional and longitudinal associations in CARDIA. Am. J. Prev. Med. 53, 764–771. https://doi.org/10.1016/j.amepre.2017.07.009 (2017).
Beran, D., Ewen, M. & Laing, R. Constraints and challenges in access to insulin: A global perspective. Lancet Diabetes Endocrinol. 4, 275–285. https://doi.org/10.1016/s2213-8587(15)00521-5 (2016).